Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by basslifton Jan 27, 2018 2:38pm

278 Views

Post# 27447492

RE:Chart Stuff for those that want it & if you don't, BLOCK ME

Ya nice to see the consolidation around 35ish as this is where it spiked up to in early December. I think at this level anyone who had bought on the highs and wanted to sell to break even would have had he chance to do so. Wasn’t much more than a year ago that this stock was trading well over $1. I see this over .50 soon enough

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity